PAL-119
unknown (auto-discovered: incretin-obesity, peptides-regenerative)
Classification
ResearchCompound
Regulatory Status
investigational; registered trials: NCT07901595 (PHASE1/PHASE2)
Unofficial source
Sources
1
Review
pending review
Overview
Unknown — PAL-119 was found by open discovery on 2026-10-29 and has not been researched yet.
Evidence and limitations
Known
n/a
Unknown
- Mechanism, dosing, safety, interactions and efficacy are unknown until research runs on this auto-discovered draft.
Study details: trial conditions, not guidance
These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.
Doses found
Doses as found in each source, with its grade. What was found, not a direction.
Studies, trials and professional sources
n/a
Reddit, Facebook, Instagram, forums and blogs
n/a
Claims and grades
- Not gradedPAL-119 is being studied in a registered trial: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes (NCT07901595; PHASE1/PHASE2; NOT_YET_RECRUITING; sponsor Paulex Bio Inc.; intervention "PAL-119" (DRUG)).
Sources (1)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes (opens in a new tab) · ClinicalTrials.gov · trial-registry · 2026-10-28
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw